Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (NASDAQ: PBYI) reported third-quarter 2026 net income of $6.0 million and raised its full-year net income guidance. Quarterly revenue reached $55.1 million, versus $54.5 million a year earlier. NERLYNX net product revenue increased to $54.1 million from $51.9 million, while diluted earnings fell to $0.11 from $0.17.
Puma now expects 2026 net income of $20–$22 million, up from $17–$20 million, but narrowed total revenue guidance to $224–$227 million from $224–$231 million. A $2.1 million royalty reduction reflected generic competition in China. Puma said higher sales deductions and partner sales delayed into the fourth quarter weighed on quarterly sales. Operating cash flow rose to $14.6 million from $9.7 million. Cash, cash equivalents and marketable securities totaled $108.5 million at September 30. Puma also initiated the Phase II ALISCA-Lung2 trial of alisertib with paclitaxel.
Puma Biotechnology (NASDAQ: PBYI) approved inducement restricted stock unit awards covering 18,500 shares for three new non-executive employees on November 2, 2026.
The awards fall under the 2017 Employment Inducement Incentive Award Plan and vest over three years, subject to continued service. Vesting begins with one-third on the first anniversary of the November 1, 2026 commencement date, followed by one-sixth on each six-month anniversary thereafter.
Puma Biotechnology (NASDAQ: PBYI) will host a conference call on November 5, 2026, to discuss its third quarter 2026 financial results. The call starts at 1:30 p.m. PT/4:30 p.m. ET, following the results release. A live webcast and presentation slides will be available on the company’s Investors website, with a replay archived for 90 days.
Puma Biotechnology (NASDAQ: PBYI) approved an inducement restricted stock unit award covering 7,500 common shares on October 1, 2026. The award went to one new non-executive employee under the 2017 Employment Inducement Incentive Award Plan. It vests over three years, with one-third vesting on the first anniversary of the October 1, 2026 vesting commencement date and one-sixth on each six-month anniversary thereafter, subject to continued service.
Puma Biotechnology (PBYI) has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer who have progressed after platinum-based chemotherapy and immunotherapy.
The sequential dose escalation study will enroll approximately 50 patients. The primary endpoint is the safety and tolerability of alisertib with paclitaxel. Secondary endpoints include objective response rate, duration of response, disease control rate, progression-free survival and overall survival. Puma will also evaluate clinical biomarkers to help identify patients most likely to benefit and to guide further development of alisertib. The company continues to advance alisertib monotherapy in the ALISCA®-Lung1 trial and views ALISCA®-Lung2 as additive to this program.
Puma Biotechnology (PBYI) will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 3:30 p.m. ET. Chairman, Chief Executive Officer, President and Founder Alan H. Auerbach will provide an overview of Puma. The conference runs September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A live webcast and presentation slides will be available via the Investors section of Puma Biotechnology’s website, with the presentation archived online for 30 days.
Puma Biotechnology (PBYI) granted inducement restricted stock unit (RSU) awards covering 33,550 shares of common stock to five new non-executive employees, effective September 1, 2026.
The awards were made under Puma’s 2017 Employment Inducement Incentive Award Plan and are intended as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years: one-third of the shares on the first anniversary of the September 1, 2026 vesting commencement date, and one-sixth of the shares on each six-month anniversary thereafter, subject to continued service.
Puma Biotechnology (NASDAQ:PBYI) reported second quarter 2026 total revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million versus $49.2 million. GAAP net income was $8.2 million, or $0.16 per basic and diluted share, compared with $5.9 million, or $0.12 per share, in 2025. Non-GAAP adjusted net income was $10.1 million, or $0.20 per basic share.
For the first six months of 2026, total revenue reached $101.3 million and GAAP net income was $4.4 million, down from $8.8 million in 2025, reflecting higher R&D spending. Puma fully repaid its 2021 notes in May 2026, eliminating debt, and ended the quarter with $93.9 million in cash, cash equivalents and marketable securities.
Based on increased NERLYNX demand, Puma raised its full-year 2026 guidance, now expecting net product revenue of $205–$209 million, total revenue of $224–$231 million and net income of $17–$20 million. The company is also advancing its ALISCA alisertib clinical trials in breast and small cell lung cancer with several expansion and data milestones targeted through 2026.
Puma Biotechnology (NASDAQ: PBYI) reported that its Board’s Compensation Committee approved inducement restricted stock unit (RSU) awards covering 35,375 shares/b) of common stock for five new non-executive employees, effective August 3, 2026.The RSUs were granted under Puma’s 2017 Employment Inducement Incentive Award Plan and will vest over three years: one-third of the shares vest on August 1, 2027, and one-sixth of the shares vest on each six-month anniversary thereafter, subject to continued service. The awards are intended as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) will host a conference call on Thursday, August 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2026 financial results. Investors can join via domestic dial-in 1-877-709-8150, international dial-in 1-201-689-8354, or a live webcast with slides on the Investors section of the company’s website. A replay will be available about one hour after the call and archived online for 90 days.